Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is sitaxsentan a safe and efficacious treatment for pulmonary arterial hypertension?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 536–537 (2006)Cite this article

boxed-textBarst RJ et al. on behalf of the STRIDE-2 study group (2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47: 2049–2056

Sitaxsentan is a new treatment option for patients with pulmonary arterial hypertension, but it is unclear whether it offers substantial benefits over bosentan, another endothelin-receptor antagonist

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hoeper MM (2005) Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs 65: 1337–1354

    Article  CAS  Google Scholar 

  2. Giaid A et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732–1739

    Article  CAS  Google Scholar 

  3. Channick RN et al. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358: 1119–1123

    Article  CAS  Google Scholar 

  4. Rubin LJ et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896–903

    Article  CAS  Google Scholar 

  5. Galie N et al. (2005) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46: 529–535

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine at the Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

    Marius M Hoeper

Authors
  1. Marius M Hoeper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marius M Hoeper.

Ethics declarations

Competing interests

MM Hoeper is a member of the scientific advisory boards of Actelion Pharmaceuticals, Encysive and Pfizer. In addition, he has received honoraria for lecturing at conferences from Actelion Pharmaceuticals, Pfizer and Schering Plough.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoeper, M. Is sitaxsentan a safe and efficacious treatment for pulmonary arterial hypertension?. Nat Rev Cardiol 3, 536–537 (2006). https://doi.org/10.1038/ncpcardio0675

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0675

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing